Evaxion Refocuses on Immuno-Oncology; Q3 Loss $3.5M, Cash $13.3M to End-2027
EVAX is trading near its 52-week low of $2.425 (4.7% above the low).
Summary
Evaxion is narrowing its pipeline to immuno-oncology, prioritizing off-the-shelf cancer vaccines EVX-04 and EVX-05, while reporting a $3.5 million Q3 net loss and $13.3 million in cash with runway into late 2027.
Key Events · Earnings and Guidance · EVAX
-
Strategy Refocused on Immuno-Oncology
Evaxion will prioritize off-the-shelf cancer vaccines EVX-04 and EVX-05 and expand EVX-01 through partnerships, while infectious disease and autoimmune work proceeds only with external funding.
-
Q3 Net Loss of $3.5 Million
No revenue was recorded in Q3 2026 versus $7.5 million a year earlier; R&D was $2.3 million and G&A $1.4 million, producing a $3.5 million net loss.
-
Cash Runway Extended to Late 2027
Cash and equivalents were $13.3 million at September 30, 2026, down from $14.0 million at June 30, supported by $2.2 million of gross ATM proceeds.
-
Equity Falls to $8.1 Million
Total equity dropped from $17.0 million at December 31, 2025 to $8.1 million at September 30, 2026, reflecting the $10.9 million nine-month net loss.
Analysis · EVAX · Life Sciences
Evaxion is dropping broad pipeline spending to concentrate on cancer vaccines, and the Q3 numbers show why: no revenue this quarter against a $3.5 million net loss, leaving $13.3 million of cash that management says funds operations into late 2027. That runway removes near-term financing pressure, but equity has fallen to $8.1 million from $17.0 million at the start of the year, and the ATM has already been used for $2.2 million of gross proceeds — so further share sales remain the likely funding path. The infectious disease programs now survive only with partner money, which puts the burden on business development rather than the balance sheet.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVAX was trading at $2.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.2M. The 52-week trading range was $2.43 to $6.92. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.